Do clinical, histological or immunohistochemical primary tumour characteristics translate into different (18)F-FDG PET/CT volumetric and heterogeneity features in stage II/III breast cancer?

MLA

Groheux, David, et al. “Do Clinical, Histological or Immunohistochemical Primary Tumour Characteristics Translate into Different (18)F-FDG PET/CT Volumetric and Heterogeneity Features in Stage II/III Breast Cancer?” European Journal of Nuclear Medicine and Molecular Imaging, vol. 42, no. 11, Oct. 2015, pp. 1682–91. EBSCOhost, https://doi.org/10.1007/s00259-015-3110-x.

APA

Groheux, D., Majdoub, M., Tixier, F., Le Rest, C. C., Martineau, A., Merlet, P., Espié, M., de Roquancourt, A., Hindié, E., Hatt, M., & Visvikis, D. (2015). Do clinical, histological or immunohistochemical primary tumour characteristics translate into different (18)F-FDG PET/CT volumetric and heterogeneity features in stage II/III breast cancer? European Journal of Nuclear Medicine and Molecular Imaging, 42(11), 1682–1691. https://doi.org/10.1007/s00259-015-3110-x

Chicago

Groheux, David, Mohamed Majdoub, Florent Tixier, Catherine Cheze Le Rest, Antoine Martineau, Pascal Merlet, Marc Espié, et al. 2015. “Do Clinical, Histological or Immunohistochemical Primary Tumour Characteristics Translate into Different (18)F-FDG PET/CT Volumetric and Heterogeneity Features in Stage II/III Breast Cancer?” European Journal of Nuclear Medicine and Molecular Imaging 42 (11): 1682–91. doi:10.1007/s00259-015-3110-x.